(Teleborsa) – News in the pharmaceutical sector. The American Pfizer has acquired Hospira , putting up $90 for each share of the pharmaceutical company specializing in injectable drugs, with a premium of 39% on the stock's close yesterday.
The deal has an enterprise value of approximately $17 billion.
The deal will be financed through a combination of cash and debt: $15.2 billion in cash plus debt assumption.
The market applauds the operation causing the Pfizer stock to jump by almost 3 percentage points. Flywheel of the 34% the Hopsira shares.
Posted on in Finance | Source: Teleborsa | Here Finance
Note: Pfizer + Hospira synergies
Hospira's CEO is F. Michael Ball, 58 years old. During the 2013 fiscal year, he received total compensation of $ 9.892.283. Hospira has 17,000 employees (as of 12/02/2014)
Pfizer's CEO is Ian C. Read, 60 years. During the 2013 fiscal year, he received a total compensation of $ 18.947.747. In 2012, Pfizer had 113,700 employees.
Pfizer Stock Exchange Valuation
Pfizer is going on the offensive in general (Les Echos)